Skip to main content
SpringerLink
Log in

High Intensity Focused Ultrasound

  • Chapter
  • First Online:
Book cover Imaging and Focal Therapy of Early Prostate Cancer

Part of the book series: Current Clinical Urology ((CCU))

  • 1432 Accesses

Abstract

Focal therapy (FT) is an emerging noncancerous tissue preservation strategy that aims for treating only the areas of cancer. FT has attracted attention over the several years in the field of treatment of localized prostate cancer. On the other hand, the use of minimally invasive ablative techniques in the management of patients with low-grade and localized prostate cancer could represent a treatment option between active surveillance and radical therapy. This ablative technology can deliver a minimally invasive, day case treatment with effective early cancer control and low genitourinary morbidity. This article reviews the evidence for FT using high intensity focused ultrasound (HIFU) in the treatment of low-risk, localized prostate cancer. Since the inclusion criterion for FT is one of the most important and urgent need to be solved, we mainly reported our considerations of eligibility for our focal HIFU in this chapter.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Villers A, McNeal JE, Freiha FS, Stamey TA. Multiple cancers in the prostate. Morphologic features of clinically recognized versus incidental tumors. Cancer. 1992;70:2313–8.

    Article  PubMed  CAS  Google Scholar 

  2. Noguchi M, Stamey TA, Mcneal JE, Nolley R. Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: lack of significance of secondary cancers. J Urol. 2003;170:459–63.

    Article  PubMed  Google Scholar 

  3. Muto S, Yoshii T, Saito K, Kamiyama Y, Ide H, Horie S. Focal therapy with high-intensity focused ultrasound in the treatment of localized prostate cancer. Jpn J Clin Oncol. 2008;38:192–9.

    Article  PubMed  Google Scholar 

  4. Han M, Partin AW, Piantadosi S, Epstein JI, Walsh PC. Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol. 2001;166:416–9.

    Article  PubMed  CAS  Google Scholar 

  5. Stokes SH. Comparison of biochemical disease-free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation. Int J Radiat Oncol Biol Phys. 2000;47:129–36.

    Article  PubMed  CAS  Google Scholar 

  6. Polascik TJ, Pound CR, DeWeese TL, Walsh PC. Comparison of radical prostatectomy and iodine 125 interstitial radiotherapy for the treatment of clinically localized prostate cancer: a 7-year biochemical (PSA) progression analysis. Urology. 1998;51:884–9.

    Article  PubMed  CAS  Google Scholar 

  7. Bahn DK, Lee F, Badalament R, Kumar A, Greski J, Chernick M. Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer. Urology. 2002;60(2 Suppl 1):3–11.

    Article  PubMed  Google Scholar 

  8. Long JP, Bahn D, Lee F, Shinohara K, Chino DO, Macaluso JN. Five-year retrospective, multi-institutional pooled analysis of cancer-related outcomes after cryosurgical ablation of the prostate. Urology. 2001;57:518–23.

    Article  PubMed  CAS  Google Scholar 

  9. Ragde H, Blasko JC, Grimm PD, Kenny GM, Sylvester JE, Hoak DC, et al. Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma. Cancer. 1997;80:442–53.

    Article  PubMed  CAS  Google Scholar 

  10. Hanlon AL, Hanks GE. Failure pattern implications following external beam irradiation of prostate cancer: long-term follow-up and indications of cure. Cancer J. 2000;6 Suppl 2:S193–7.

    PubMed  Google Scholar 

  11. Martinez AA, Gonzalez JA, Chung AK, Kestin LL, Balasubramaniam M, Diokno AC, et al. A comparison of external beam radiation therapy versus radical prostatectomy for patients with low risk prostate carcinoma diagnosed, staged, and treated at a single institution. Cancer. 2000;88:425–32.

    Article  PubMed  CAS  Google Scholar 

  12. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2011;59:572–83.

    Article  PubMed  Google Scholar 

  13. Kamidono S, Ohshima S, Hirao Y, Suzuki K, Arai Y, Fujimoto H, et al. Evidence-based clinical practice guidelines for prostate cancer (summary – JUA 2006 edition). Int J Urol. 2008;15:1–18.

    Article  PubMed  CAS  Google Scholar 

  14. Steineck G, Helgesen F, Adolfsson J, Dickman PW, Johansson JE, Norlén BJ, et al. Scandinavian Prostatic Cancer Group Study Number 4. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med. 2002;347:790–6.

    Article  PubMed  Google Scholar 

  15. Hoznek A, Menard Y, Salomon L, Abbou CC. Update on laparoscopic and robotic radical prostatectomy. Curr Opin Urol. 2005;15:173–80.

    Article  PubMed  Google Scholar 

  16. Barqawi A, Crawford ED. Focal therapy in prostate cancer: future trends. BJU Int. 2005;95:273–4.

    Article  PubMed  Google Scholar 

  17. Miller DC, Gruber SB, Hollenbeck BK, Montie JE, Wei JT. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst. 2006;98:1134–41.

    Article  PubMed  Google Scholar 

  18. Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst. 2002;94:981–90.

    Article  PubMed  Google Scholar 

  19. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137–50.

    Article  PubMed  Google Scholar 

  20. Sakr WA, Haas GP, Cassin BF, Pontes JE, Crissman JD. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol. 1993;150:379–85.

    PubMed  CAS  Google Scholar 

  21. D’Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol. 2003;21:2163–72.

    Article  PubMed  Google Scholar 

  22. Bostwick DG, Waters DJ, Farley ER, Meiers I, Rukstalis D, Cavanaugh WA, et al. Group Consensus Reports from the Consensus Conference on Focal Treatment of Prostatic Carcinoma Celebration, Florida. Urology. 2006;70:42–4.

    Article  Google Scholar 

  23. Eggener SE, Scardino PT, Carroll PR, Zelefsky MJ, Sartor O, Hricak H, et al. International task force on prostate cancer and the focal lesion paradigm: focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol. 2007;178:2260–7.

    Article  PubMed  Google Scholar 

  24. Crawford ED, Barqawi A. Targeted focal therapy: a minimally invasive ablation technique for early prostate cancer. Oncology. 2007;21:27–32.

    PubMed  Google Scholar 

  25. Rebillard X, Soulié M, Chartier-Kastler E, Davin JL, Mignard JP, Moreau JL, et al. High-intensity focused ultrasound in prostate cancer; a systematic literature review of the French Association of Urology. BJU Int. 2008;101:1205–13.

    Article  PubMed  Google Scholar 

  26. Van Leenders GJ, Beerlage HP, Ruijter ET, de la Rosette JJ, van de Kaa CA. Histopathological changes associated with high intensity focused ultrasound (HIFU) treatment for localised adenocarcinoma of the prostate. J Clin Pathol. 2000;53:391–4.

    Article  PubMed  Google Scholar 

  27. Kennedy JE. High-intensity focused ultrasound in the treatment of solid tumours. Nat Rev Cancer. 2005;5:321–7.

    Article  PubMed  CAS  Google Scholar 

  28. Fujisue Y, Azuma H, Inamoto T, Komura K, Agarwal PY, Masuda H, et al. Neoadjuvant hormonal therapy does not impact the treatment success of high-intensity focused ultrasound for the treatment of localized prostate cancer. World J Urol. 2011;29:689–94.

    Article  PubMed  CAS  Google Scholar 

  29. Blana A, Murat FJ, Walter B, Thuro VS, Wieland WF, Chaussy C, et al. First analysis of the long-term results with transrectal HIFU in patients with localised prostate cancer. Eur Urol. 2008;53:1194–201.

    Article  PubMed  Google Scholar 

  30. Blana A, Walter B, Rogenhofer S, Wieland WF. High-intensity focused ultrasound for the treatment of localized prostate cancer: 5-year experience. Urology. 2004;63:297–300.

    Article  PubMed  Google Scholar 

  31. Gelet A, Chapelon JY, Bouvier R, Rouviere O, Lyonnet D, Dubernard JM. Transrectal high-intensity focused ultrasound for the treatment of localized prostate cancer: Factors influencing the outcome. Eur Urol. 2001;40:124–9.

    Article  PubMed  CAS  Google Scholar 

  32. Thuroff S, Chaussy C, Vallancien G, Wieland W, Kiel HJ, Le Duc A, et al. High-intensity focused ultrasound and localized prostate cancer: efficacy results from the European multicentric study. J Endourol. 2003;17:673–7.

    Article  PubMed  Google Scholar 

  33. Vallancien G, Prapotnich D, Cathelineau X, Baumert H, Rozet F. Transrectal focused ultrasound combined with transurethral resection of the prostate for the treatment of localized prostate cancer: feasibility study. J Urol. 2004;171:2265–7.

    Article  PubMed  Google Scholar 

  34. Chaussy G, Thuroff S, Rebillard X, Gelet A. Technology insight: high-intensity focused ultrasound for urologic cancers. Nat Clin Pract Urol. 2005;2:191–8.

    Article  PubMed  Google Scholar 

  35. Illing RO, Leslie TA, Kennedy JE, Calleary JG, Ogden CW, Emberton M. Visually directed high-intensity focused ultrasound for organ-confined prostate cancer: a proposed standard for the conduct of therapy. BJU Int. 2006;98:1187–92.

    Article  PubMed  Google Scholar 

  36. Ahmed HU, Freeman A, Kirkham A, Sahu M, Scott R, Allen C, et al. Focal therapy for localized prostate cancer: a phase I/II trial. J Urol. 2011;185:1246–54.

    Article  PubMed  CAS  Google Scholar 

  37. ElFegoun AB, Barret E, Prapotnich D, Soon S, Cathelineau X, Rozet F, et al. Focal therapy with high-intensity focused ultrasound for prostate cancer in the elderly. A feasibility study with 10 years follow-up. Int Braz J Urol. 2011;37:213–22.

    Google Scholar 

  38. Zelefsky MJ, Ben-Porat L, Scher HI, Chan HM, Fearn PA, Fuks ZY, et al. Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer. J Clin Oncol. 2005;23:826–31.

    Article  PubMed  Google Scholar 

  39. D’Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med. 2004;351:125–35.

    Article  PubMed  Google Scholar 

  40. Goto Y, Ohori M, Arakawa A, Kattan MW, Wheeler TM, Scardino PT. Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. J Urol. 1996;156:1059–63.

    Article  PubMed  CAS  Google Scholar 

  41. Graefen M, Ohori M, Karakiewicz PI, Cagiannos I, Hammerer PG, Haese A, et al. Assessment of the enhancement in predictive accuracy provided by systematic biopsy in predicting outcome for clinically localized prostate cancer. J Urol. 2004;171:200–3.

    Article  PubMed  Google Scholar 

  42. Tsuzuki T, Hernandez DJ, Aydin H, Trock B, Walsh PC, Epstein JI. Prediction of extraprostatic extension in the neurovascular bundle based on prostate needle biopsy pathology, serum prostate specific antigen and digital rectal examination. J Urol. 2005;173:450–3.

    Article  PubMed  Google Scholar 

  43. Naya Y, Slaton JW, Troncoso P, Okihara K, Babaian RJ. Tumor length and location of cancer on biopsy predict for side specific extraprostatic cancer extension. J Urol. 2004;171:1093–7.

    Article  PubMed  Google Scholar 

  44. Kestin LL, Goldstein NS, Vicini FA, Martinez AA. Percentage of positive biopsy cores as predictor of clinical outcome in prostate cancer treated with radiotherapy. J Urol. 2002;168:1994–9.

    Article  PubMed  CAS  Google Scholar 

  45. Shukla-Dave A, Hricak H, Kattan MW, Pucar D, Kuroiwa K, Chen HN, et al. The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: an initial analysis. BJU Int. 2007;99:786–93.

    Article  PubMed  CAS  Google Scholar 

  46. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999;341:1781–8.

    Article  PubMed  CAS  Google Scholar 

  47. Wieland WF, Blana A. PSA nadir is a significant predictor of treatment failure after high-intensity focussed ultrasound (HIFU) treatment of localised prostate cancer. Eur Urol. 2008;53:547–53.

    Article  PubMed  Google Scholar 

  48. Kim CK, Park BK, Lee HM, Kim SS, Kim E. MRI techniques for prediction of local tumor progression after high-intensity focused ultrasonic ablation of prostate cancer. AJR. 2008;190:1180–6.

    Article  PubMed  Google Scholar 

  49. Rouviere O, Girouin N, Glas L, Ben Cheikh A, Gelet A, Mège-Lechevallier F, et al. Prostate cancer transrectal HIFU ablation: detection of local recurrences using T2-weighted and dynamic contrast-enhanced MRI. Eur Radiol. 2010;20:48–55.

    Article  PubMed  Google Scholar 

  50. Rouviere O, Lyonnet D, Raudrant A, Colin-Pangaud C, Chapelon JY, Bouvier R, et al. MRI appearance of prostate following transrectal HIFU ablation of localized cancer. Eur Urol. 2001;40:265–74.

    Article  PubMed  CAS  Google Scholar 

  51. Cirillo S, Petracchini M, D’Urso L, Dellamonica P, Illing R, Regge D, et al. Endorectal magnetic resonance imaging and magnetic resonance spectroscopy to monitor the prostate for residual disease or local cancer recurrence after transrectal high-intensity focused ultrasound. BJU Int. 2008;102:452–8.

    Article  PubMed  Google Scholar 

  52. Sciarra A, Panebianco V, Salciccia S, Osimani M, Lisi D, Ciccariello M, et al. Role of dynamic contrast-enhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer. Eur Urol. 2008;54:589–600.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Teikyo University, 2-11-1, Kaga, Itabashi-ku, Tokyo, 173-8605, Japan

    Satoru Muto M.D., Ph.D. & Shigeo Horie M.D.

Authors
  1. Satoru Muto M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shigeo Horie M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Satoru Muto M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. , Department of Surgery, Duke Cancer Institute, Room 1089 Duke South, Durham, 27710, North Carolina, USA

    Thomas J. Polascik

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Muto, S., Horie, S. (2013). High Intensity Focused Ultrasound. In: Polascik, T. (eds) Imaging and Focal Therapy of Early Prostate Cancer. Current Clinical Urology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-182-0_20

Download citation

  • DOI: https://doi.org/10.1007/978-1-62703-182-0_20

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-62703-181-3

  • Online ISBN: 978-1-62703-182-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation